mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation.

Trial Profile

mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 May 2017

At a glance

  • Drugs Everolimus (Primary) ; Antithymocyte globulin; Basiliximab; Ciclosporin
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms EVEROLD
  • Most Recent Events

    • 03 May 2017 Results of a preliminary analysis comparing everolimus versus MPA (n=33), presented at the 2017 American Transplant Congress
    • 07 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 28 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top